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Tripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) act as ACE inhibitors in vitro. Double transgenic rats
(dTGR) harbouring human renin and human angiotensinogen genes develop malignant hypertension due to increased angiotensin
II formation. The present study was aimed to evaluate possible antihypertensive effect of IPP and VPP in this severe model. Four-
week-old dTGR were randomized in three groups to receive: (1) water (control), (2) fermented milk containing IPP and VPP,
and (3) IPP and VPP dissolved in water for three weeks. Fermented milk, but not peptides in water, attenuated the development
of hypertension in dTGR by 19 mmHg versus the control group (P = .023). In vitro vascular function tests showed that high
concentrations of the peptides evinced ACE inhibitory properties. In other hypertension related variables, no significant differences
between the treatment groups were found. In conclusion, fermented milk product containing IPP and VPP prevents development
of malignant hypertension in an animal model.
1. Introduction
Fermented milk products containing biologically active
tripeptides, isoleucyl-prolyl-proline (IPP) and valyl-prolyl-
proline (VPP), have been shown to attenuate the develop-
ment of hypertension in spontaneously hypertensive rats
(SHRs) [1–4] and to reduce blood pressure in mildly
hypertensive subjects [5–10]. These antihypertensive pep-
tides have been reviewed in detail recently [11–14]. The
present hypothesis as to the antihypertensive effect is that
of angiotensin-converting enzyme (ACE) inhibition, which
has been shown both in vitro and in vivo [1, 3, 15, 16]. In
addition, fermented milk containing IPP and VPP lowers
ACE activity in the aorta [17] and elevates plasma renin
activity (PRA) in a long-term treatment of SHRs [3].
Furthermore, these peptides protect endothelial function in
vitro during a 24-hour incubation [18].
Despite these findings, the exact antihypertensive mech-
anisms behind IPP and VPP have not been confirmed.
As described previously, double transgenic rats (dTGR)
harbouring human renin and human angiotensinogen genes
develop malignant hypertension, cardiac hypertrophy, renal
damage, and endothelial dysfunction due to increased
angiotensin II (Ang II) formation by the transfected human
genes [19–21]. Inhibitors of ACE and renin, and AT1
receptor antagonists have been shown to reduce blood
pressure and vascular inflammatory responses, decrease
adhesion molecule expression in the kidneys, and improve
endothelial function in dTGR [22]. Thus, these animals are
considered to be a sensitive model for studying agents which
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are thought to modify the function of the renin-angiotensin
system (RAS).
The aim of the present study was to evaluate the pos-
sible antihypertensive effect of fermented milk preparation
containing IPP and VPP, and the pure peptides in drinking
water, for the first time in this severe model of hypertension,
dTGR, which overexpresses RAS. The role of ACE inhibitory
activity of IPP and VPP, and their effects on hypertension
related biochemical markers, were also studied.
2. Material andMethods
2.1. Animals and Diets. The study protocol was approved
by the Animal Experimentation Committee of the Institute
of Biomedicine, Helsinki, Finland. Four-week-old body-
weight-matched (61±2.2 g) dTGRs harbouring human renin
and human angiotensinogen genes in a Sprague-Dawley
(SD) background (Biotechnology and Animal Breeding Divi-
sion, Fu¨llinsgdorf, Switzerland) were used. The treatment
groups (n = 15 in the control group and n = 10 in the
fermented milk and peptide groups in the beginning of the
study) were as follows:
(1) Control group: dTGR + water as drinking fluid (n = 9
at the end of the treatment period),
(2) Fermented milk group: dTGR + milk product contain-
ing IPP (1.8 mg/100 mL) and VPP (1.8 mg/100 mL)
(Valio Ltd, Helsinki, Finland) (n = 6 at the end of the
treatment period),
(3) Peptide group: dTGR + IPP (3.4 mg/100 mL) and
VPP (3.4 mg/100 mL) (IPP and VPP, Bachem AG,
Bubendorf, Switzerland) in water as drinking fluid
(n = 8 at the end of the treatment period).
The concentration of the peptides in the drinking
fluid was based on our previous experience on the fluid
consumption of spontaneously hypertensive rats in similar
experiments (2–4). The animals had free access to feed
(2018, Harlan Nederland, Horst, The Netherlands) and
drinking fluid during the whole 3-week treatment period.
Normotensive Sprague-Dawley rats of the same age (water
as drinking fluid) served as healthy controls to see the age
related changes in blood pressure.
2.2. Blood Pressure Measurement. Systolic blood pressure
was measured by using a tail-cuff blood pressure analyser
(IITC Life Science, Woodland Hills, CA, USA). Before
measurement, the rats were kept at +32◦C for 15 minutes
to improve the detection of the pulse of the tail artery.
The systolic blood pressure value was defined as a mean of
three successful measurements without disturbances of the
signal.
2.3. Fluid and Feed Consumption. Fluid consumption was
monitored daily and feed consumption weekly. The energy
nutrient and mineral contents in the fermented milk, as well
as the IPP and VPP contents to control their preservation,
were analysed by the peptide research group in Valio Ltd
(Helsinki, Finland). The tripeptide content of Lactobacillus
helveticus fermented milk was determined by the modified
method of Masuda et al. [23], by collecting the peptide
fraction by gel filtration chromatography (Superdex Peptide
HR 10/30 Amersham Pharmacia Biotech, Bucks, UK) and
analysing it by reversed phase HPLC (Waters Alliance HPLC
system, Milford, MA, USA), using synthetic peptides as
standards.
2.4. In Vitro ACE Inhibitory Activity. The mesenteric artery
was cleaned of adherent connective tissue. Three-mm-long
arterial rings were placed between stainless steel hooks and
suspended in an organ bath chamber in Krebs-Ringer buffer
(pH 7.4) of the following compositions (mM): NaCl 119.0,
NaHCO3 25.0, glucose 11.1, CaCl2 1.6, KCl 4.7, KH2PO4 1.2,
and MgSO4 1.2, and aerated with 96% O2 and 4% CO2.
The rings were equilibrated for 45 minutes at +37◦C with
a resting tension of 1.0 g. The presence of the functional
endothelium of the preparations was confirmed by observ-
ing an endothelium-dependent relaxation response to the
1 µM acetylcholine (ACh) in the 1 µM noradrenaline (NA)
precontracted arterial rings. The ACE inhibitory activity of
IPP and VPP in vitro was determined by preincubating the
arterial rings from normotensive Sprague-Dawley rats with
tripeptides for 10 minutes and measuring the response to a
single administration of angiotensin I (1 µM) or angiotensin
II (1 µM).
2.5. Urine, Plasma, and Tissue Samples. During weeks 1 and 3
of the treatment period, the rats were housed individually in
metabolic cages for 24 hours. The consumption of drinking
fluids and feed was measured and the intake of energy
nutrients, minerals, and IPP and VPP was calculated during
the 24-hour period (Table 1). Urine volumes were measured
and samples were stored at −80◦C for microalbumin mea-
surements.
At the end of the study, the rats were rendered uncon-
scious with CO2/O2 (95%/5%) (AGA, Riihima¨ki, Finland)
and decapitated. The blood samples were put into chilled
glass tubes with EDTA as an anticoagulant. The blood
samples were centrifuged (1800×g, 20 minutes, +4◦C), and
the plasma separated and stored at −80◦C until analysed.
The heart and kidneys were removed, washed with saline,
blotted dry and weighed, and the ratios to body weight were
calculated.
2.6. Biochemical Determinations. Urinary albumin excretion
was measured by ELISA, using rat albumin as a standard
(Celltrend GmbH, Luckenwalde, Germany). Plasma renin
activity (PRA) was measured using a radioimmunoassay of
angiotensin I (Medix Angiotensin I test, Medix Biochem-
ica, Kauniainen, Finland); aldosterone was measured by
radioimmunoassay (Diagnostic Products Co, Los Angeles,
CA, USA); and plasma B-type natriuretic peptide (BNP) was
measured by radioimmunoassay as described in detail earlier
[24].
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Table 1: Body weight, urine volume, and the intake of feed, fluids and minerals during the 24-hour period in metabolic cages at the end of
the three-week treatment period (mean ± SE, n = 6–9).
Variable Control Fermented milk Peptide Difference between the groups, P
Body weight, g 235 ± 13 221 ± 11 239 ± 7 .53
Urine volume, mL 33 ± 3 33 ± 4 44 ± 4 .085
Feed intake, g 26 ± 1 16 ± 1 26 ± 0.5 <.001
Fluid intake, mL 37 ± 4 24 ± 8 47 ± 4 .032
Energy, kJ 352 ± 15 285 ± 27 353 ± 7 .014
Sodium, mg 59 ±2 44 ± 3 60 ± 1 <.001
Potassium, mg 175 ± 7 188 ± 28 175 ± 3 .76
Calcium, mg 260 ± 11 213 ± 21 261 ± 5 .025
Magnesium, mg 51 ± 2 36 ± 2 52 ± 1 <.001
2.7. Renal Morphology. For morphological studies, the renal
samples were fixed in 4% buffered paraformaldehyde at
room temperature, dehydrated in graded alcohol, and
embedded in paraffin. Two-to-three-µm sections were cut
with a microtome and placed on glass. The sections were
deparaffinised and rehydrated before staining with Masson’s
trichrome. Renal damage was analysed in a blinded fashion
and divided into four scores of 0–4 (0 = normal and 4 =
severe damage) as described previously [25].
2.8. Statistics. The results are expressed as means with stan-
dard errors (SE). Statistically significant differences between
the groups were tested by permutation type ANOVA with
Hommel’s adjustment if appropriate. Permutation type test
was used because there are a small number of observations
in each group and assumptions underlying to corresponding
parametric test cannot be relied on.
3. Results
3.1. Body Weight and Blood Pressure. Body weight gain
development was similar between the groups during the
3-week treatment (Table 1). Already in the beginning of
the study, 4-week-old dTGRs were clearly hypertensive,
with systolic blood pressure about 160 mmHg (Figure 1).
The development of severe hypertension was fast, about
25 mmHg in a week in the dTGR control and peptide groups,
but less in the fermented milk group, about 15 mmHg in
a week (Figure 1). At the end of the treatment period, the
mean blood pressure was 192±4 mmHg in the control group,
174± 5 mmHg in the fermented milk group, and 189± 4 in
the peptide group (Figure 1) (P = .023 between the groups).
The blood pressure of the normotensive SD rats remained at
the same level during the whole study period (132±2 mmHg
in the beginning and 128± 1 mmHg in the end of the study,
not shown in the figure).
During the treatment period, six rats from the controls,
two rats from the peptide group, and four rats from the
fermented milk group died during nights and therefore could
not be autopsied.
3.2. Fluid and Feed Consumption. In daily measurements of
the fluid intake, there were no differences between the groups
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Figure 1: The mean (±SE) systolic blood pressure in different
treatment groups. The number of animals in the beginning of
the experiment: control 15, fermented milk and peptide groups
10/group. Week 3: 9, 6 and 8, respectively, (P = .023 between the
groups).
and also the energy intake was similar between the groups
(data not shown). This explains the similar body weight
at the end of the experiment. The mean estimated daily
peptide intake (IPP+VPP) during the whole study period
was 5.4 mg/kg in the fermented milk group and 10.9 mg/kg
in the peptide group. However, the 24-hour monitoring in
metabolic cages, showed differences in the feed and fluid
intake being lowest in the fermented milk group (Table 1).
Therefore, calcium, magnesium, and sodium intake was also
lowest in the fermented milk group, respectively. Based on
these data, the peptide intake (IPP+VPP) during the 24-hour
monitoring was 4.1±1.1 mg/kg body weight in the fermented
milk group and 14.1 ± 1.4 mg/kg in the peptide group.
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Table 2: Biochemical variables and cardiac and renal hypertrophies at the end of the three-week treatment period (mean ± SE, n = 6–9).
Variable Control Fermented milk Peptide Difference between the groups, P
Urinary albumin, mg/d 22 ± 4 35 ± 8 30 ± 4 .20
PRA, ng Ang I/mL/h 90 ± 17 99 ± 30 95 ± 19 .98
BNP, pmol/L 3.1 ± 0.5 2.3 ± 0.2 3.5 ± 0.3 .24
Aldosterone, pg/mL 1228 ± 302 2551 ± 921 1494 ±218 .18
Cardiac hypertrophy index (mg/g) 5.3 ± 0 5.1 ± 0 5.1 ± 0 .59
Renal hypertrophy index (mg/g) 4.6 ± 0 4.8 ± 0 4.8 ± 0 .61
These contradictory findings in metabolic caging may be due
to too short period for the animals to become acclimatized in
a new environment. Therefore, the repeated daily recordings
can be regarded more reliable.
3.3. In Vitro Bioassay of ACE Inhibitory Activity. To test the
ACE inhibitory activity of IPP and VPP in the in vitro
bioassay, mesenteric artery rings of normotensive SD rats
were used. IPP and VPP (0.33 mM) administered together
inhibited 84% of the angiotensin I (1 µM)-induced contrac-
tion, but did not reduce angiotensin II-induced contraction.
3.4. Cardiac and Renal Hypertrophy. The dTGRs showed
marked cardiac and renal hypertrophy compared to the
normotensive SD controls. Neither fermented milk nor
peptides affected the heart or kidney weight to body weight
ratios (Table 2).
3.5. Renal Morphology. The arteriales of untreated dTGRs
showed perivascular inflammation and concentric hypertro-
phy with medial and intimal proliferations. The glomeruli
had notable mesangial expansion. The tubules were only
minimally affected.
The damage score was 3.3 ± 0.2 in the dTGR control
group, 3.0 ± 0.3 in the fermented milk group, and 2.8 ± 0.2
in the peptide group (P = .53).
3.6. Biochemical Determinations. During the treatment
period, all the dTGR groups developed severe albuminuria,
compared to the healthy SD controls (P < .05), as a marker of
renal damage according to the renal damage score. At the end
of the treatment period, there was no difference in albumin
excretion between the three treatment groups (Table 2).
Aldosterone values tended to be highest in the fermented
milk group. However, the difference did not reach statistical
significance obviously due to large variations. There was no
statistical difference between the groups in PRA or BNP
(Table 2).
4. Discussion
The present study with double transgenic rats harbouring
human renin and angiotensinogen genes aimed to evaluate
the blood-pressure-lowering effect and its mechanisms of the
two casein-derived tripeptides IPP and VPP in a fermented
milk product. According to previous studies by us [2–
4] and others [1] using spontaneously hypertensive rats,
the present study shows for the first time that milk-based
products containing these peptides act antihypertensively
even in a malignant form of experimental hypertension. ACE
inhibitory activity of the pure peptides was confirmed in
vitro, but the effect could not been seen in vivo despite
prevention of hypertension.
The difference from the control group was of the same
magnitude (about 20 mmHg) as in our previous studies on
SHRs [2–4]. The attenuation in blood pressure development
was not seen in the peptide group, despite the higher
intake of peptides compared to the fermented milk group.
Thus the antihypertensive effect of fermented milk cannot
be explained alone by the ACE inhibitory activity of IPP
and VPP, contrary to the earlier findings on a less severe
hypertension model, SHR [3]. The antihypertensive effect
of fermented milk may also be related to other components
such as favourable milk mineral contents, more calcium and
potassium, and less sodium, as suggested and shown by
us recently [4]. The bioavailability of the peptides versus
peptides in water may be improved by other milk compo-
nents. Furthermore, caseinophosphopeptides are known to
increase the absorption of calcium [26, 27], a blood pressure
lowering electrolyte [28, 29]. The antihypertensive effect of
fermented milk might also relate to other effects of milk-
derived peptides [30] or other antihypertensive mechanisms
related to the RAS or L-type calcium channels as described
recently on some synthetic dipeptides [31].
One explanation for the fairly weak antihypertensive
and lack of biochemical effects in the fermented milk
group and the lack of effect in the peptide group may
be the short treatment period, low dose of peptides, and
the fast development of severe hypertension with death of
the animals. In our earlier experimental [2–4] and clinical
studies [6, 7], the antihypertensive effect was first seen after
five or six weeks of treatment, which was not possible in the
present study.
The intake of tripeptides in the fermented milk group
and the peptide group remained lower than in our earlier
studies [2–4]. The present doses may not have been sufficient
to antagonise the severe hypertension of dTGRs caused by
an over-expressed RAS, although ACE inhibition has been
shown in SHRs in vitro and in vivo [2–4]. In our previous
studies [2, 4], peptides in water have also been less effective
than the fermented milk product in lowering blood pressure
possibly due to their weaker bioavailability from water. Only
partial intestinal absorption of the unmetabolized di- or
tripeptides has been demonstrated in the rat [32], in the pig
[33], and in man [34, 35].
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Biochemical determinations did not show clear differ-
ences between the groups in any of the markers. With
this rat model, therefore, ACE inhibition does not seem to
explain the blood pressure lowering effect in the fermented
milk group. According to a previous study [36], the plasma
concentration of BNP was elevated in dTGRs related to
cardiac pressure. The peptide treatments in this study were
not able to antagonise clearly this increase. It may be that this
ineffectiveness can be explained by the lack of clear cardiac
hypertrophy in the present study. However, the slightly lower
BNP value in the fermented milk group could indicate lower
risk for cardiac hypertrophy, if it were possible to continue
the experiment longer.
There are two major concerns in the study. Firstly, due
to fast development of severe hypertension, part of the
animals, mainly from the untreated (control) group, died
during the intervention thus weakening the power of the
study. Furthermore, from the same reason the intervention
period remained shorter than that in our previous studies
where the antihypertensive effect has been more evident [2–
4]. Secondly, there is discrepancy between the continuous
feed and drinking fluid recording and the data from 24-
hour metabolic caging. The former seems to be more reliable,
because the body weight development did not differ and daily
observation of the animals did not indicate markers of poor
physical condition.
5. Conclusions
The present study shows that the weak ACE inhibitory
activity of IPP and VPP in drinking water is not able to
prevent the severe hypertension in this rapidly developing
hypertension model, although the antihypertensive effect is
evident in SHRs. However, the peptides in fermented milk
clearly antagonized the increase in blood pressure suggesting
improved kinetics of the peptides in this product or other
active components present.
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